23andMe cuts 40% of its workforce and discontinues therapeutics division
Me is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the ...
23andMe Lays Off 40 Percent of its Staff, Ends All Therapy Programs
As founder and CEO Anne Wojcicki struggles to take the company private, 200 jobs are cut as part of its restructuring plan.
23andMe Slashes Workforce By 40%, Ends Therapeutic Programs
The therapeutic programs of 23andMe include an antibody that restores the ability of the immune system to kill cancer cells.
Wall Street Journal23h
23andMe Lays Off 40% of Staff, Shuts Drug Development Business
DNA-testing company 23andMe and its founder, Anne Wojcicki, aimed to revolutionize healthcare, bringing genetic tests into homes with just a tube of spit. WSJ takes a look at the factors that have ...
DNA-testing site 23andMe fights for survival
Once millions used it to find out about their family histories - this week it was almost delisted. What went wrong?
Nasdaq14d
23andMe Holding Expands Board with New Appointments
They will join CEO Anne Wojcicki in steering 23andMe towards ... This strategic move positions the company for future growth in the genetics-led consumer healthcare market. See more data about ...
NBC Connecticut14d
23andMe appoints three new board members following abrupt resignations
Andre Fernandez, Jim Frankola and Mark Jensen will join the company's CEO Anne Wojcicki on the board. The new board members are Andre Fernandez, the former chief financial officer of WeWork ...
NBC New York14d
23andMe appoints three new board members following abrupt resignations
Andre Fernandez, Jim Frankola and Mark Jensen will join the company's CEO Anne Wojcicki on the board. The new board members are Andre Fernandez, the former chief financial officer of WeWork; Jim ...